NCT05965739Completed
RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms
RECOVER-NEURO: A Platform Protocol for Evaluation of Interventions for Cognitive Dysfunction in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
Source: ClinicalTrials.gov · Last updated 11 Aug 2026
Brief summary (registry, in English)
This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating potential interventions for PASC-mediated cognitive dysfunction. The hypothesis is that PASC-associated dysfunction in cognitive domains, such as executive function and attention, may be improved by interventions that selectively focus on enhancing those domains. This design seeks to evaluate each intervention relative to the Active Comparator. The BrainHQ (alone) arm is important because the intervention is commercially available, accessible, relatively inexpensive, and does not require trained personnel to administer. BrainHQ has been also been proven effective in other studies of cognitive dysfunction such as studies in aging, mild cognitive impairment, traumatic brain injury, among others. The BrainHQ + PASC CoRE arm and the BrainHQ + tDCS arms are suspected to provide cognitive improvements beyond BrainHQ alone through different mechanisms. Both PASC CoRE and tDCS have extensive prior use and have demonstrated utility in improving aspects of cognitive function in other clinical settings..
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 328 (actual)
- First submitted
- 25 Jul 2023
- Start date
- 1 Sept 2023
- Primary completion date
- 19 Sept 2024
- Lead sponsor
- Duke University
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT05965739
What you commit to
- Study type: Interventional
- Participants enrolled: 328
- From 1 Sept 2023 to the primary completion date, 19 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Skin disorders or skin-sensitive areas near tDCS stimulation locations that would interfere with electrode placement or increase the risk of stimulation-induced damage, at the investigator's discretion
Other
- 1\. See NCT05965752 for RECOVER-NEURO: Platform Protocol level exclusion criteria which applies to this appendix
- Additional Appendix (Sub-study) Level Exclusion Criteria:
- Presence of metal objects in the head or neck
Who the study is looking for
- 1\. See NCT05965752 for RECOVER-NEURO: Platform Protocol level inclusion criteria which applies to this appendix
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| All sites listed under NCT05965752 Coordinator of this site? Confirm its status | Durham | United States | Unknown status |
Related publications
- Evaluation of Interventions for Cognitive Symptoms in Long COVID: A Randomized Clinical Trial.JAMA Neurol · 2026 · PMID 41212544
This page is information, not medical advice. Discuss any trial with your doctor.